[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adenomyosis-of-uterus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adenomyosis-of-uterus":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,55,95,120,177,201,230,260],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100053246","linzagolix-in-adenomyosis-and-recurrent-implantation-failure-100053246",false,"NCT07698561","Linzagolix in Adenomyosis and Recurrent Implantation Failure","Efficacy of Linzagolix 200 mg for 3 to 6 Months Prior to Embryo Transfer in Patients With Adenomyosis and Recurrent Implantation Failure: A Prospective Case Series","LINZA-RIF","Inclusion Criteria:\n\n* Age 18 to 50 years\n* Confirmed adenomyosis by transvaginal ultrasound or MRI\n* Recurrent implantation failure defined as 2 or more failed embryo transfers with high-quality blastocysts: oocyte donation recipients (blastocyst grade BB or above, Gardner classification) OR autologous IVF cycles with PGT-A confirmed euploid blastocysts\n* Normal uterine cavity with no submucosal distortion\n* At least 1 suitable embryo available for transfer (blastocyst grade BB or above, or PGT-A euploid)\n* Signed written informed consent including explicit acknowledgement of off-label use of linzagolix\n\nExclusion Criteria:\n\n* Untreated hydrosalpinx\n* Untreated stage III-IV endometriosis\n* Major uterine anomaly (uterine septum, bicornuate uterus)\n* Known contraindication to linzagolix including known hepatopathy\n* Prior treatment with linzagolix\n* GnRH analogue treatment within 6 months prior to enrolment\n* BMI greater than 35 kg\u002Fm2\n* Prior failed transfers exclusively with embryos below the quality threshold (below BB grade, non-euploid)","FEMALE","18 Years","50 Years",{"count":21,"type":22},35,"ESTIMATED","2 Years","OBSERVATIONAL","Adenomyosis is associated with impaired endometrial receptivity and reduced implantation rates in assisted reproduction, even when using high-quality embryos. Linzagolix (Yselty, 200 mg) is an oral GnRH receptor antagonist approved for uterine fibroids with a favourable tolerability profile and rapid elimination half-life (18-20 hours) compared to GnRH agonists.\n\nThis prospective case series evaluates the efficacy of linzagolix 200 mg administered for 3 to 6 months prior to embryo transfer in patients with confirmed adenomyosis and recurrent implantation failure (RIF), defined as ≥2 failed transfers with high-quality blastocysts (≥BB Gardner in oocyte donation, or PGT-A confirmed euploid in autologous cycles).\n\nThe primary endpoint is the live birth rate (LBR) per embryo transfer. Secondary endpoints include clinical pregnancy rate, miscarriage rate, morphological response of adenomyosis (uterine volume and junctional zone \\[JZ\\] thickness assessed by standardised transvaginal ultrasound), and tolerability profile. The study also explores the optimal treatment duration (3 vs 6 months) as a sub-analysis based on morphological response at the month-3 visit.\n\nThe study is conducted at three centres of Vida Fertility Institute (Madrid, Alicante and San Sebastián, Spain). Sample size: n=35 patients. Study duration: 24 months.",[27,28,29,30],"Adenomyosis of Uterus","Implantation Failure","Infertility Female","Embryo Transfer",[32,33,34,35,36,37,38,39,40,41],"Linzagolix","Yselty","adenomyosis","recurrent implantation failure","junctional zone","live birth rate","oocyte donation","PGT-A","GnRH antagonist","endometrial receptivity","NOT_YET_RECRUITING","2026-07-06",{"date":45,"type":46},"2026-07-13","ACTUAL",{"date":48,"type":22},"2026-09-01",{"date":50,"type":22},"2028-09-01",{"name":52,"class":53},"Vida Fertility Institute","INDUSTRY",3,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":77,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":94},"100644230","phase-4-cyclobenzaprine-for-postoperative-pain-in-minimally-invasive-hysterectomy-100644230","NCT07664956","Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy","Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age \\>18yo\n* Female\n* English speaking\n* Undergoing (robotic assisted or classic) total laparoscopic hysterectomy ± unilateral or bilateral salpingectomy ± unilateral or bilateral oophorectomy\n* If other procedures such as lysis of adhesions, excision of endometriosis, or ureterolysis are indicated based on intraoperative evaluation, those patients may still be included\n* Surgery took place at ChristianaCare Hospitals\n* No allergies or contraindications to standard of care post operative pain medications (acetaminophen, NSAIDs, narcotics) or cyclobenzaprine\n\nExclusion Criteria:\n\n* Age \\\u003C18yo\n* Male\n* Pregnant, breastfeeding\n* Non-English speaking\n* Primary procedures other than laparoscopic hysterectomy\n* Laparoscopic myomectomy\n* Laparoscopic resection of endometriosis\n* Laparoscopic unilateral or bilateral salpingectomy ± unilateral or bilateral oophorectomy ± unilateral or bilateral cystectomy without hysterectomy\n* Hysteroscopic procedures\n* Bartholin gland marsupialization\n* Operations that are scheduled as or converted to the open approach\n* Procedures with planned or unplanned bladder or bowel surgery\n* Allergies or contraindications to standard post operative pain control medications (acetaminophen, NSAIDs, narcotics), such as kidney or liver damage\u002Ffailure, bariatric surgery, history of gastric ulcer, etc.\n* Chronic pain issues, whether self-diagnosed or by a physician, currently undergoing management\n* Currently undergoing medication assisted treatment for opioid use disorder\n* Currently using opioids consistently\n* Allergies or contraindications to cyclobenzaprine:\n* Absolute: use of MAO inhibitors within 14 days, recent heart attack, congestive heart failure, heart block or other conduction abnormalities, cardiac arrhythmias, hyperthyroidism, history of serotonin syndrome\n* Allergies or contraindications to inactive ingredients in Flexeril, such as lactose\n* Patient's receiving gabapentin at baseline or postoperatively, due to potential sedating effects, or other sedating drugs such as scheduled benzodiazepines and barbiturates",{"count":63,"type":22},36,"INTERVENTIONAL",[66],"PHASE4","Typical postoperative pain control after minimally invasive hysterectomy includes ibuprofen, acetaminophen, and a short course of narcotics. The purpose of this study is to see if adding cyclobenzaprine to this regime improves pain control and lessens narcotic use.",[69,70,27,71,72,73,74,75,76],"Minimally Invasive Surgical Procedures","Abnormal Uterine Bleeding, Unspecified","Fibroid Uterus","Chronic Pelvic Pain","Endometriosis","Menorrhagia","Endometritis","Adnexal Diseases",[78,79,80,81,82,83],"cyclobenzaprine","flexeril","hysterectomy","minimally invasive hysterectomy","pain control","multimodal pain control","2026-06-18",{"date":86,"type":46},"2026-06-24",{"date":88,"type":22},"2026-07-01",{"date":90,"type":22},"2026-12-01",{"name":92,"class":93},"Christiana Care Health Services","OTHER",1,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":102,"maxAge":19,"enrollmentInfo":103,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":94},"100629741","multicenter-observational-cohort-study-on-the-epidemiology-of-therapeutic-strategies-in-patients-affected-by-adenomyosis-100629741","NCT07478614","Multicenter Observational Cohort Study on the Epidemiology of Therapeutic Strategies in Patients Affected by Adenomyosis","Adenomyosis","Inclusion Criteria:\n\nAge between 20 and 50 years; Instrumental (ultrasound or MRI) and\u002For histological diagnosis of adenomyosis; Adenomyosis-associated pain with a VAS score ≥ 4 and\u002For presence of heavy menstrual bleeding (HMB) defined as a score \\> 100 on the Pictorial Blood Assessment Chart (PBAC); Provision of written informed consent to participate in the study; Willingness to be followed at the participating center for the entire duration of the study.\n\nExclusion Criteria:\n\nCurrent or previous clinical and\u002For instrumental diagnosis of endometriosis; Suspected or confirmed pregnancy; Inability to understand the purpose of the study and to provide informed consent.","20 Years",{"count":104,"type":22},200,"The primary objective of this multicenter observational cohort study is to evaluate the current medical approach to the management of adenomyosis in women, with particular focus on treatment selection and treatment persistence. The secondary objective is to identify the criteria guiding therapeutic choices in daily clinical practice within a multicenter setting.\n\nAdenomyosis is a benign gynecological condition characterized by the presence of endometrial-like epithelial and stromal tissue within the myometrium. It mainly affects women aged 41 to 45 years and typically presents with symptoms such as chronic pelvic pain, dysmenorrhea, and menorrhagia. The most commonly used treatments include GnRH agonists, progestins, and intrauterine devices (IUDs); however, there are no universally accepted guidelines for the management of this condition, and therapeutic options remain a matter of debate.\n\nThis is a multicenter observational cohort study with both prospective and retrospective recruitment of women affected by adenomyosis. Italian clinical centers will be included and will recruit patients aged between 20 and 50 years, with a diagnosis of adenomyosis confirmed by ultrasound or magnetic resonance imaging (MRI) and\u002For histology, and presenting significant symptoms (VAS ≥ 4 for pelvic pain or bleeding \\> 100 on the Pictorial Blood Assessment Chart - PBAC). Cases of concomitant endometriosis, pregnancy, and conditions preventing informed consent will be excluded.\n\nEach center will collect data regarding the prescribed treatment, its effectiveness, and treatment persistence over time. The study duration will be 12 months, with data collection at baseline (V0), 3 months (V1), 6 months (V2), and 12 months (V3). Approximately 200 patients will be enrolled across 20 centers, with an enrollment period of 12 months.\n\nThe analysis will be conducted based on the frequency of treatment use and changes in treatment response in relation to age, symptoms, and other clinical factors.\n\nData Collection Methodology\n\nPatients will undergo regular clinical evaluations at 3 months, 6 months, and 12 months. Data will be collected using validated questionnaires (VAS, PBAC, SF-12). Transvaginal ultrasound examinations will be performed, and ferritin and hemoglobin levels will be measured. Treatment adherence and tolerability will be monitored through interviews and the recording of adverse events (AEs), including serious adverse events (SAEs).\n\nData Analysis\n\nThe analysis will be descriptive, focusing on the frequency of prescribed treatments and patient characteristics (age, symptoms, comorbidities). Continuous variables will be analyzed using mean and standard deviation (for normally distributed data) or median and range (for non-normally distributed data), while categorical variables will be analyzed using proportions and 95% confidence intervals. Differences between groups will be explored using appropriate statistical tests.\n\nExpected Results and Implications\n\nThis study will provide crucial information on the epidemiology of therapeutic approaches to adenomyosis in Italy, helping to bridge existing knowledge gaps and supporting the development of evidence-based recommendations for clinical management. The results will help guide medical practice, improve patients' quality of life, and contribute to the development of therapeutic guidelines.\n\nDissemination of Results\n\nThe study results will be published in scientific articles in international peer-reviewed journals, with active participation of the physicians involved in the research.",[27,107,108,109],"Uterine Diseases","Gynecologic Diseases","Menorrhagia, Dysmenorrhea","RECRUITING","2026-03-13",{"date":113,"type":46},"2026-03-17",{"date":115,"type":46},"2025-06-01",{"date":117,"type":22},"2027-02-01",{"name":119,"class":93},"SCHETTINI SERGIO",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":128,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":129,"targetDuration":131,"studyType":24,"phases":4,"briefSummary":132,"conditions":133,"keywords":134,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":54},"100623521","association-of-ultrasound-features-of-the-myometrium-suggestive-of-adenomyosis-and-clinical-symptoms-100623521","NCT07397715","Association of Ultrasound Features of the Myometrium Suggestive of Adenomyosis and Clinical Symptoms","Association of Ultrasound Features of the Myometrium Suggestive of Adenomyosis and Clinical Symptoms (MUSA 3)","MUSA3","Inclusion Criteria:\n\n* Women of pre- and perimenopausal age presenting for gynaecologic ultrasound exam giving voluntary informed written consent.\n* Symptomatic and asymptomatic women\n* Patients with hormonal contraceptives and Hormone Replacement Therapy (HRT) can be included, but information will be noted.\n\nExclusion Criteria:\n\n* Missing written consent (study consent)\n* Any serious underlying medical, psychiatric or psychological condition, which may interfere with the patient's capacity of discernment.\n* Postmenopausal women\n* Pregnancy\n* History of pelvic urogynaecologic surgery (TVT, mesh surgery, etc.)\n* Malignancy or premalignancy of uterus\u002Fcervix\n* Prior myomectomy for FIGO 3-6 fibroids\n* Patients with coagulation disorders under current anticoagulation medication\n* Prior history of diagnosed intraabdominal adhesions (surgery)\n* Prior diagnosis of pelvic congestion syndrome\n* Psychiatric disease precluding a reliable estimation of pain\n* Prior surgery or treatment for deep infiltrating endometriosis\n* Acute other symptoms:\n* Urinary symptoms (dysuria, urgency, grade III stress incontinence)\n* Acute of chronic pelvic infection (cervicitis, endometritis, salpingitis, frozen pelvis)\n* Ovarian lesions\n* Sonographic signs of deep infiltrating endometriosis (DIE)\n* Intracavitary pathology (Fibroid 0-2, polyp, adhesions)\n* Retained products of conception\n* \\>3 small fibroids below 2 cm in largest diameter FIGO 3-8 (i.e. the presence of three fibroids below 2cm is NOT considered an exclusion criterion)\n* Presence of any fibroid \\>2cm.",true,{"count":130,"type":22},1000,"1 Day","The goal of this study\u002Fresearch is to assess the relationship between ultrasound features of the myometrium suggestive of adenomyosis and clinical symptoms of adenomyosis and to establish a reporting system for adenomyosis assessing disease severity. Consecutive pre- and perimenopausal symptomatic and asymptomicasymptomatic women with an uterus presenting for gynaecological ultrasound exams will be asked to participate in the study. Routine gynecologicalgynaecological ultrasound exams will be performed and study participants will fill out a questionnaire on their symptoms (if any) and bleeding pattern. There will be one visit and no interventions.",[27],[135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166],"Adenomyoma","Deep infiltrating endometriosis","Gynaecological transvaginal ultrasound","Gynaecological Ultrasound","Myometrium","Uterine anomaly","Asymptomatic adenomyosis","Symptomatic adenomyosis","Menstrual bleeding","Bleeding disorders","Abnormal uterine bleeding","Abdominal pain","Dysmenorrhoea","Dyspareunia","Morphological Uterus Sonographic Assessment (MUSA)","Adenomyosis Grading","Subfertility","Ultrasound features","Myometrial cysts","Hyperechogenic island","Echogenic subendometrial lines and buds","Globular uterus","Asymmetrical myometrial thickening","Fan shaped shadowing","Cyclical\u002Fnon-cyclical bleeding","menorrhagia","Metrorrhagia","Translesional vascularity","Irregular junctional zone","Interrupted junctional zone","benign fibroid","Myoma","2026-02-11",{"date":169,"type":46},"2026-02-12",{"date":171,"type":46},"2024-03-15",{"date":173,"type":22},"2029-02-01",{"name":175,"class":176},"Swiss GO Trial Group","NETWORK",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":17,"minAge":102,"maxAge":184,"enrollmentInfo":185,"targetDuration":4,"studyType":64,"phases":187,"briefSummary":189,"conditions":190,"keywords":191,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":197,"leadSponsor":199,"locationsCount":4},"100605472","phase-3-nintedanib-for-improving-reproductive-outcomes-in-adenomyosis-100605472","NCT07162961","Nintedanib for Improving Reproductive Outcomes in Adenomyosis","A Single-center, Randomized, Prospective, Controlled Clinical Study on the Efficacy of Nintedanib in Improving Reproductive Outcomes in Women With Adenomyosis","Inclusion Criteria:\n\nAged 20-38, diagnosed with primary or secondary infertility; with at least one vitrified high-quality blastocyst (grading ≥4BB).\n\nDiagnosed with adenomyosis within the last 3 months by MRI or transvaginal ultrasound, meeting the criteria of the Chinese Expert Consensus on Diagnosis and Treatment of Adenomyosis.\n\nBody Mass Index (BMI) between 18-27 kg\u002Fm².\n\nRegular menstrual cycles, no amenorrhea or severe dysfunctional uterine bleeding.\n\nNormal ovarian reserve (AMH \\> 1 ng\u002FmL or AFC ≥ 5 per ovary), not currently receiving ovarian suppression therapy.\n\nSigned informed consent, able to understand and voluntarily participate, and willing not to participate in other clinical trials during the study period.\n\nExclusion Criteria:\n\nUterine or adnexal abnormalities (e.g., intrauterine adhesions, unicornuate\u002Fbicornuate\u002Farcuate uterus, unremoved hydrosalpinx, endometrial polyp, submucosal myoma, or intramural myoma distorting the endometrial cavity).\n\nHistory of GnRH agonist injection within 3 months prior to embryo transfer.\n\nUnexplained abnormal vaginal bleeding.\n\nKnown active pelvic inflammatory disease.\n\nKnown genital malformation unsuitable for pregnancy.\n\nAbnormal cervical cytology (TCT) results within 1 year before screening.\n\nSevere impairment of liver or kidney function, heart disease, or hypertension.\n\nKnown history of thrombophlebitis or thromboembolic disease.\n\nAny known clinically significant systemic disease (e.g., diabetes, tuberculosis).\n\nKnown history of recurrent miscarriage.\n\nChromosomal karyotype abnormality in either partner.\n\nEither partner has a genetic disease deemed unsuitable for childbearing per the \"Maternal and Infant Health Care Law\".\n\nEither partner has been exposed to teratogenic levels of radiation, toxins, or drugs.\n\nAny condition\u002Fcombined surgery\u002Fmedication\u002Fother clinically significant abnormal lab finding judged by the investigator to potentially affect trial results.\n\nKnown refusal or inability to comply with the protocol requirements for any reason.","38 Years",{"count":186,"type":22},328,[188],"PHASE3","This study aims to evaluate the effectiveness and safety of nintedanib, an antifibrotic drug, in improving live birth rates for infertile women with adenomyosis who have frozen embryos. Based on promising animal data showing reduced uterine fibrosis, participants will be randomized to receive either standard progesterone therapy plus nintedanib or progesterone therapy alone for three months before undergoing a frozen embryo transfer cycle.",[27],[100,192],"nintedanib","2025-09-01",{"date":195,"type":46},"2025-09-09",{"date":193,"type":22},{"date":198,"type":22},"2027-06-30",{"name":200,"class":93},"Sun Yat-sen University",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":17,"minAge":102,"maxAge":184,"enrollmentInfo":209,"targetDuration":4,"studyType":64,"phases":211,"briefSummary":213,"conditions":214,"keywords":216,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":94},"100597980","gnrh-agonist-pretreatment-duration-and-letrozole-supplementation-in-frozen-embryo-transfer-for-adenomyosis-patients-100597980","NCT07065539","GnRH Agonist Pretreatment Duration and Letrozole Supplementation in Frozen Embryo Transfer for Adenomyosis Patients","The Impact of Duration of Gonadotropin-Releasing Hormone Agonist Pretreatment and Letrozole Supplementation on Pregnancy Outcomes in Frozen-Thawed Embryo Transfer Cycles for Patients With Adenomyosis: A 2 by 2 Factorial Multicenter, Randomized Controlled Trial","GOLD-FET","Inclusion Criteria:\n\n* Sonographically diagnosed adenomyosis via transvaginal ultrasound;\n* Candidates scheduled for frozen single blastocyst (Day5, Day6) transfer\n* Age 20-38 years\n* Previous embryo transfer attempts: ≤2 cycles\n\nExclusion Criteria:\n\n* Patients diagnosed with Recurrent pregnancy loss, Autoimmune disorders (e.g., systemic lupus erythematosus), Uterine fibroids ≥5 cm, Cervical incompetence, Cesarean scar niche\n* History of Myomectomy and\u002For adenomyosis lesion excision, Cervical conization\n* Patients presenting with Congenital Müllerian anomalies (unicornuate uterus, septate uterus, etc.), Endometrial atypical hyperplasia, malignancy or defects\n* Sperm retrieval method: Micro-TESE (microdissection testicular sperm extraction)\n* Fertilization method: Rescue ICSI\n* Endometrial thickness \\\u003C7 mm, Intrauterine adhesions, Intrauterine fluid\n* Contraindications to exogenous hormone administration\n* Use of GnRH within 3 months prior to enrollment",{"count":210,"type":22},432,[212],"NA","This randomized clinical trial aims to assess the comparative effectiveness of different pre-treatment protocols prior to frozen embryo transfer (FET) among women with adenomyosis, providing evidence-based guidance for clinical decision-making. The main questions it aims to answer are:\n\nDoes the protocol involving two doses of gonadotropin-releasing hormone agonist (GnRH-a) pretreatment result in a higher live birth rate compared to one dose of GnRH-a pretreatment in women with adenomyosis undergoing frozen embryo transfer? Does the protocol involving GnRH-a with letrozole supplementation result in a higher live birth rate compared to GnRH-a monotherapy in women with adenomyosis undergoing frozen embryo transfer? Eligible participants will undergo screening before endometrial preparation for FET, following which they will be randomly assigned to one of four groups: GnRH-a-1M, GnRH-a-2M, GnRH-a+LE-1M or GnRH-a+LE-2M. In the GnRH-a-1M group, participants will be pre-treated with one dose GnRH agonist before endometrial preparation. In the GnRH-a-2M group, participants will be pre-treated with two doses GnRH agonist before endometrial preparation. In the GnRH-a+LE-1M group, participants will be pre-treated with one dose GnRH agonist and letrozole 28 days before endometrial preparation. In the GnRH-a+LE-2M group, participants will be pre-treated with two doses GnRH agonist, along with daily 2.5 mg letrozole for 28 days since the first injection of GnRH agonist before endometrial preparation. After pre-treament, all participants will return for endometrial preparation in artificial cycles.",[27,215],"Frozen Embryo Transfer (FET)",[34,217,218,219,220],"embryo transfer","GnRH-a","letrozole","pre-treament","2025-07-14",{"date":223,"type":46},"2025-07-15",{"date":225,"type":22},"2025-07-20",{"date":227,"type":22},"2027-12",{"name":229,"class":93},"First Affiliated Hospital, Sun Yat-Sen University",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":238,"targetDuration":4,"studyType":64,"phases":240,"briefSummary":241,"conditions":242,"keywords":244,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":94},"100591804","phase-4-does-the-addition-of-letrozole-to-ultra-long-gnrh-agonists-help-adenomyosis-patients-in-art-the-aura-trial-100591804","NCT06985186","Does The Addition Of Letrozole To Ultra-Long GnRH Agonists Help Adenomyosis Patients in ART? The AURA Trial","The Effect of Adenomyosis Following Ultra-long GnRH Agonists With or Without Aromatase Inhibitors on ART Outcomes (AURA Trial): a Randomized Controlled Trial","AURA","Inclusion Criteria:\n\n\\- Infertile patients affected by adenomyosis diagnosed by 2D-3D transvaginal ultrasound according to revised Morphological Uterus Sonographic Assessment consensus.\n\nExclusion Criteria:\n\n* concomitant uterine fibroids,\n* Müllerian malformations,\n* endometrial pathology,\n* thin endometrium,\n* hydrosalpinx,\n* mucometra,\n* previous surgery except for previous cesarean section,\n* coagulation disorders,\n* untreated endocrinopathies,\n* severe seminal pathologies,\n* double ET,\n* ET different from the first one after adenomyosis treatment.",{"count":239,"type":22},162,[66],"The AURA Trial seeks to improve fertility treatment for women affected by a condition known as adenomyosis. Adenomyosis often leads to heavy menstrual bleeding, pelvic pain, dyspareunia and can make it more difficult to achieve and maintain a healthy pregnancy.\n\nIn this randomized controlled trial participating women ≥ 18 years of age with a confirmed imaging diagnosis of adenomyosis according to Morphological Uterus Sonographic Assessment (MUSA) consensus will first undergo a thorough assessment. This initial workup includes reviewing medical history, assessing the characteristics of the uterus (volume, myometrial architecture, shape of the uterine cavity, stiffness, etc.) via 2D\u002F3D transvaginal ultrasound, and obtaining blood tests to establish baseline hormone levels.\n\nOnce enrolled, each participant will be assigned at random-without prior knowledge by either the woman or her care team-to one of two 90-day pre-treatment regimens. The first group will receive monthly injections of a GnRH agonist, a medication that temporarily suppresses ovarian function and lowers estrogen levels. The second group will follow the same injection schedule but will also take daily letrozole tablets, an aromatase inhibitor that further reduces estrogen production. The hope is that this combined approach will calm the inflammatory environment caused by adenomyosis, promote a more receptive uterus, and ultimately increase the likelihood of an embryo developing beyond the critical 12-week mark.\n\nAt the end of the 90-day protocol, and after repeating all evaluations carried out during the enrolment phase, all women will proceed with the planned assisted reproductive technology cycle with the usual careful monitoring until the day of emrbyo transfer. To ensure correct interpretation of the results and to minimise the potential effect of any incompetent oocytes, only euploid embryos evaluated by pre-implantation genetic test or embryos derived from donated oocytes will be transferred. Pregnancy will be assessed first with a blood test, followed by an ultrasound scan at approximately six or seven weeks to confirm a clinical pregnancy. An ongoing pregnancy, defined by the detection of the fetal heartbeat beyond the 12th week, is the main measure of success.\n\nBy participating in AURA, women and their families not only gain access to cutting-edge clinical care but also contribute valuable knowledge that could shape future standard treatments for adenomyosis-related infertility. For further information or to explore participation, please reach out to the Instituto Bernebu Assisted Reproduction Center, where our team is ready to guide you through every step of this important study.",[27,243],"Infertility Assisted Reproductive Technology",[34,245,246,247,248,249,250],"infertility","Ultra-Long GnRH Agonists","Aromatase inhibitor","IVF outcomes","assisted reproductive technology","egg-donation","2025-05-22",{"date":253,"type":46},"2025-05-29",{"date":255,"type":22},"2025-06",{"date":257,"type":22},"2026-12",{"name":259,"class":93},"University of Palermo",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":266,"enrollmentInfo":267,"targetDuration":4,"studyType":64,"phases":269,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":4},"100573821","evaluation-of-the-efficacy-and-safety-of-microwave-ablation-of-uterine-adenomyosis-under-improved-ultrasound-guidance-100573821","NCT06751264","Evaluation of the Efficacy and Safety of Microwave Ablation of Uterine Adenomyosis Under Improved Ultrasound Guidance","Inclusion Criteria:\n\n1. UFs or AM diagnosed by pathology and ultrasound；\n2. Relevant symptoms such asabnormal uterine bleeding, secondary anemia, progressive dysmenorrhea and enlargement of the uterus；\n3. Voluntarily undergo MWA；\n4. a confirmed available safe transabdominal puncture path；\n\nExclusion Criteria:\n\n1. Pregnancy or malignancy；\n2. Severe and uncorrectable coagulation disorders；\n3. Severe cardiac, liver, and renal dysfunction；\n4. Anesthesia allergy.","60 Years",{"count":268,"type":22},137,[212],"This study aims to compare the safety and efficacy of segmental power adjustment combined with uterine cavity hydro-isolation in microwave ablation of adenomyosis",[27],"2024-12-20",{"date":274,"type":46},"2024-12-27",{"date":276,"type":22},"2025-01-01",{"date":278,"type":22},"2027-12-31",{"name":280,"class":93},"Peking University Aerospace Center Hospital"]